comparemela.com

Latest Breaking News On - Multiple myeloma - Page 7 : comparemela.com

Could you help clinical trial learn more about rare condition's potential link to cancer?

Researchers are looking for 20 people to take part in a clinical study in Wolverhampton which aims to improve knowledge of why a rare condition can lead to cancer.

United-kingdom
New-cross
Lewisham
Wednesfield
Wolverhampton
Supratik-basu
Lorraine-tidmarsh
Oxford-university-hospitals
Foundation-trust
Undetermined-significance
Multiple-myeloma
Royal-wolverhampton

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sundar-jagannath
Oncologic-drugs-advisory-committee
Tisch-cancer-institute
Multiple-myeloma
Mount-sinai
Drugs-advisory-committee

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;.

United-kingdom
United-states
London
City-of
Stevenage
Hertfordshire
American
Julia-wilson
June-dec
Susana-noonan
Olivia-manser
Ravi-rao

EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and.

Spain
Australia
Rockville
Pennsylvania
United-states
China
Madrid
Nanfang
Guangdong
Florida
Hong-kong
Peking

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.